© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Retapamulin began its journey in the late 20th century as researchers dug deep into the chemical landscape of pleuromutilin antibiotics. The original pleuromutilin molecule came from a fungus discovered in the 1950s, and scientists kept chipping away at its structure over decades. They aimed to build something with a sharper edge against bacterial skin infections. Retapamulin started as one of the first pleuromutilins developed for human, rather than veterinary, use. Medicinal chemists modified the basic skeleton of the pleuromutilin class, aiming for a molecule that could fight Gram-positive bacteria on the skin without giving those germs much room to develop resistance. In 2007, the FDA gave its blessing to Retapamulin ointment, opening the door for it to address impetigo and similar stubborn infections. Its story speaks as much to relentless curiosity as to the rising need for new weapons against antibiotic resistance.
The ointment sits in medicine cabinets around the world and fights against skin infections caused by Streptococcus pyogenes and Staphylococcus aureus. As a topical treatment, Retapamulin bypasses some of the hurdles common with systemic antibiotics, like gut flora disturbance or high risk of driving resistance in the entire microbiome. Packaged at a concentration of 1% in petroleum-based ointment, this medicine works right at the site of infection instead of floating through the bloodstream. This direct approach reduces the odds of side effects that sometimes come with oral or injectable antibiotics. For families and doctors, Retapamulin offers another option when old standards like mupirocin run into resistant bacteria. The fact that it's prescription-only keeps it from being overused, which matters when fighting infectious diseases that seem to learn our tricks faster every year.
Retapamulin presents as a yellowish-white substance under normal conditions. Chemically, its molecular formula is C27H43NO4S and its structure fits the macrolide-like pleuromutilin scaffold, with unique modifications on the tricyclic core. Its molecular weight hits around 473.7 g/mol. The molecule contains both polar and non-polar regions, making it just soluble enough in organic solvents but not happy to dissolve in water. This property fits its job as a topical antibiotic, since it needs to stick around on the skin without getting washed away by sweat or a light rinse. Its melting point sits in the range of 181-185°C. These physical traits don’t just satisfy chemistry fans—they shape the absorption, stability, and patient experience of the ointment.
Retapamulin ointment carries a clear set of directions and safety notices on the label. Each gram contains 10 mg of retapamulin in a soft, spreadable base, often white petrolatum and mineral oils. Storage guidelines call for keeping it at room temperature, away from children and direct sunlight to prevent breakdown. Labels spell out that the ointment goes only on skin, never in eyes, mouth, or on mucous membranes. Manufacturers must list the precise lot numbers, expiration dates, and exact contents for traceability. The labeling also highlights the need to finish the prescribed course of treatment, warding off partial dosing that could nudge bacteria toward resistance. For pharmacists and clinics, such strict technical details offer a lifeline, creating a paper trail in the event of any adverse events or recalls. Such thorough labeling embodies both safety and trust in pharmaceutical practice.
Synthesizing retapamulin draws on the chemistry backbone built during pleuromutilin research. The process often starts with fermentation to obtain pleuromutilin, the natural parent compound. This substance undergoes a series of targeted chemical reactions, including selective oxidation and acid-catalyzed ring opening, building the core skeleton. The next steps call for protecting groups and precise addition of side chains at the C-14 and C-21 positions, which transform simple pleuromutilin into the more potent retapamulin structure. Each reaction must be tightly controlled to avoid side products that carry toxic or inactive properties. Final purification steps involve chromatography and crystallization, with careful attention paid to removing solvents and impurities. What lands inside each ointment tube comes at the tail end of a remarkably precise operation—one that balances large-scale needs with the scrutiny expected of modern pharmaceuticals.
Researchers got creative with the pleuromutilin core as they sought a molecule that would dodge old patterns of resistance. Chemical modifications center on the tricyclic diterpene skeleton, especially at those C-14 and C-21 spots. Introducing a thioether group at the C-14 position helps drive the antibacterial effect by tightening the drug’s grip on the ribosomal binding site of bacteria. The side chain at C-21 increases stability while boosting resistance to common bacterial enzymes that chew up antibiotics. These modifications go far beyond cosmetic tweaks—instead, they give retapamulin its unique abilities. In the lab, chemists keep testing structural changes, exploring how they might open up new classes of drugs or further enhance skin penetration, selectivity, or half-life. Each new analog gives researchers clues about what it takes to outwit tough bacteria without driving more resistance.
Retapamulin shows up in chemical registries and pharmaceutical databases under several names. Its main synonym is SB-275833, derived from its code during GlaxoSmithKline’s development program. Some references use names like Altabax and Altargo, brand names that signal their approved uses in different countries. Its chemical identity stays rooted in its formal name, 11,14-dihydroxy-14-(propylthio)-3,7,13-trimethyl-10-oxo-4,5,6,7,10,11,12,13-octahydro-1H-cyclopenta[a]phenanthren-17-yl acetate. Regulatory listings also pin it by its CAS number, a unique identifier that helps professionals track substances even as brand names shift. These synonyms keep things clear for doctors, pharmacists, and researchers who may encounter the medicine in different regions or publication languages.
Retapamulin holds regulatory approval across Europe, the US, and a handful of other developed countries, but those include strict checks on safety and manufacturing practices. The manufacturing facilities comply with Good Manufacturing Practice (GMP) standards, including clean room protocols and validated equipment. During development and batch production, every step must pass rigorous in-process and final product testing, from verifying chemical purity to detecting potential impurities and contaminants. Healthcare workers get regular training on proper dispensing, storage, and patient counseling—critical, since incorrect use can feed the growth of superbugs. Patients receive clear warnings about avoiding application near their eyes, discontinuing use if they develop allergic rashes, and seeking care if infections worsen or don’t heal. The risk of systemic side effects stays low, but rare allergic reactions, local irritation, and contact dermatitis deserve careful attention. Such vigilance creates a safety net for both patients and healthcare systems under mounting pressure from antibiotic-resistant bacteria.
Doctors turn to retapamulin mainly for uncomplicated skin infections such as impetigo, especially those caused by Gram-positive bacteria like Staphylococcus aureus, including strains resistant to older topical treatments but not MRSA. The ointment also offers value against secondarily infected traumatic lesions, lacerations, and abrasions—problems seen in clinics and urgent care centers every day. Dermatology practices keep it on hand for cases where other topical antibiotics produce allergic reactions or face resistance. It works well as a first-line option in pediatric settings, since its topical application reduces the need for challenging oral or injectable prescriptions in children. Its scope stays focused on mild, localized infections, since studies did not support its use in deep, systemic, or MRSA-driven problems. For those narrow but vital roles, retapamulin fills a gap in the arsenal, especially as old staple antibiotics lose ground every year.
The launch of retapamulin fired up a burst of new inquiry into pleuromutilin antibiotics, not just in human healthcare but also in veterinary medicine. Teams at academic and pharmaceutical labs kept working the molecular scaffold to see how tweaks—especially on the C-14 and C-21 side chains—could arm future compounds against resistant bacteria. Interest surged in using similar structures for other infections, including respiratory diseases and animal health, given the growing need for antibiotics outside the beta-lactam and macrolide families. Studies dove into alternative formulations, like gels and sprays, and tried to understand how retapamulin performs on wounds or burns, especially under conditions where pus or dense tissue might limit penetration. Researchers also explored synergy with other antibiotics, hoping to delay resistance or shorten treatment courses. Funding keeps flowing, since every new antibiotic option offers a chance to stave off the post-antibiotic era dreaded in medical circles.
Safety sits at the center of drug development, especially for new antibiotics where off-target effects can erode trust or even harm patients. Toxicity testing for retapamulin included acute, sub-chronic, and chronic exposure studies in multiple animal models. Skin sensitization, irritation, and long-term mutagenicity all came under the microscope. The results generally supported its good safety profile in topical use, with mild, self-limiting irritation the main concern in clinical trials. Systemic absorption runs low when applied as directed, limiting systemic toxicity even in children or elderly patients. Research teams tested the compound for carcinogenicity, reproductive toxicity, and effects on fetal development, turning up little risk at clinically relevant doses. Post-marketing monitoring remains essential, pulling in data from adverse reaction reports worldwide and adjusting labeling or warnings as rare side effects emerge. Countries updating their guidelines draw on this international body of data, working to ensure that new resistance-fighting options don't trade one set of problems for another.
Doctors, patients, and researchers all hope retapamulin paves the way for a whole new class of antibiotics, especially as resistance closes off tried-and-true treatments. Next steps involve expanding its use into new formulations for wounds or mucosal infections, as well as investigating oral or systemic analogs for tougher infections. Some research focuses on combining pleuromutilin antibiotics with other molecules to reset the clock on resistance or treat infections where multiple bacteria coexist. The idea of customizing delivery—using creams, sprays, hydrogels—drives work in both clinical and materials science labs. Broader studies on resistance patterns shape how doctors select and cycle antibiotics, keeping the molecule useful for as long as possible. Technology may also squeeze better data from smart sensors and patient trackers, documenting outcomes and driving smarter antibiotic stewardship. Investment in new chemical analogs means hope remains that retapamulin may spark a new wave of innovation, offering fresh solutions in a world where superbugs never rest.
Retapamulin lives in that special spot on pharmacy shelves where comfort meets chemistry. Most days, people reach for antibiotic ointments without thinking twice about the science backing up that tiny tube. For retapamulin, it’s more than medicine—it's a tool hospitals and clinics lean on, especially for skin infections that sneak up on kids and adults alike. Healthcare in my community depends on choices like this, as we see skin problems every week, most often among children and older folks with feeble immune systems.
This ointment takes on impetigo, a highly contagious infection that targets patches of skin, making it crusty and red. I’ve seen how fast impetigo spreads through daycares and shared living spaces. While other ointments work, retapamulin stands out because Staphylococcus aureus and Streptococcus pyogenes—two tough bacteria—don’t shrug it off as easily. For families and doctors tired of seeing old antibiotics fail, retapamulin brings hope. It gives an option once the usual creams stop helping.
Doctors appreciate retapamulin because it takes a different approach. Instead of copying penicillin or bacitracin, retapamulin stops bacteria from making the proteins they need to grow. This unique action means bacteria are less likely to resist the cream. It only works on the skin, which makes it safe to use, even for little kids. The FDA stamped its approval on retapamulin in 2007—not centuries ago, but recent enough to trust its safety record. Since then, thousands of prescriptions have shown it works where it counts: in busy clinics and home medicine cabinets.
Antibiotic resistance keeps doctors up at night. Too many families now face infections that ignore old-fashioned ointments. In my experience, seeing patients cycle through three or four failed treatments before getting something effective drains more than wallets—it wears down hope. Retapamulin helps slow this race. By using a new kind of action, it keeps the bacteria guessing, making resistance harder. Studies in the British Journal of Dermatology and the New England Journal of Medicine show low rates of resistance among impetigo patients using retapamulin. This evidence matters in a world where new antibiotics rarely land on drugstore shelves.
There’s an old habit of reaching for whatever tube is cheapest or most familiar. But my days talking with parents and caregivers taught me that using targeted medicines reduces the risk of clogging up the fight against infections. Doctors who keep up with evidence honor their patients by reaching for retapamulin when the infection calls for it, not just as a last resort. Pharmacists and nurses also play a role, teaching families to finish every course—even if redness fades early—to stop bacteria from learning any new tricks.
When schools, clinics, and community centers stay aware of the tools available, we stand a better chance of keeping infections in check. Retapamulin isn't a magic barrier, but it gives another layer of protection for folks who count on getting better quickly without risking a more serious infection.
Retapamulin focuses the fight on bacteria that still respond to treatment. Used correctly, it helps communities win small battles against impetigo and may limit MRSA from spreading. This isn’t fancy science—it’s practical, proven medicine.Retapamulin shows up in clinics when a bacterial skin infection strikes, like impetigo. As someone who’s spent years coaching people through daily health habits, I’ve seen how folks can stumble through the basics of using ointments. Simple errors—applying too much, skipping steps, or not finishing the course—can end up drawing out the problem. Before grabbing that tube, it helps to know not just what it’s for, but why following the small details matters.
Every treatment starts by washing hands. Skin picks up germs across doorknobs, phones, shared towels—you name it. Wash your hands with soap and water, not just before and after, but also after touching any skin problem. Then, gently clean the infected area. Skip harsh scrubbing, even if the urge to ‘get it clean’ is strong. Warm water and a mild cleanser work best; rough handling or hot water can break the skin further.
Pat the skin dry with a fresh towel. Don’t use old rags or yesterday’s towel. Bacteria hang out in those fibers. Now, open the ointment—just enough to use, don’t squeeze out a blob the size of a walnut. Apply a thin layer to the area. Most doctors I know always say “thin” because people tend to slather on medicine thick, thinking it works better. Instead, a thin, even layer right over the infection lets the drug do its job while skin can still breathe.
Hands get washed again. Even if it takes a few seconds, this lowers the chance of spreading bacteria to eyes, nose, or another patch of skin.
A light, sterile bandage keeps outside germs out and medicine in. Not every situation calls for a bandage, but kids and folks who pick at spots, or if the area touches clothes all day, benefit most from some coverage.
Doctors write instructions for a reason. Stop early and bacteria may start fighting back, creating stronger infections. Even when things look better after two or three days, the full course—often five days—wipes out those not-yet-visible germs. Peel back the bandage, clean, reapply ointment, and replace the covering each time. Toss used bandages and wash hands, again.
Some people ask about side effects. Small irritation—mild redness or burning—sometimes shows up. In most cases, this passes. If the swelling grows or a rash spreads beyond the treated area, call a healthcare provider. Allergies show up with hives or breathing trouble. This kind of reaction needs urgent attention.
Doctors and pharmacists know that people often share what works for them, but don’t pass ointment to others or use it for just any rash. This medicine focuses on certain skin infections and offers little benefit anywhere else. Avoid eyes, nose, and mouth, because the ointment stings in those areas and future trouble can start with one wrong move.
A clean routine, finished course, and alert mind make all the difference. Health care teams, my own included, want phone calls if something feels off partway through treatment. Trust that feedback—catching small issues early avoids bigger headaches later.
Kids often spread skin infections at school or day care. Keep sores covered and teach children handwashing. Retapamulin can’t do everything alone. Sticking to good habits makes a difference at home, at work, and in the neighborhood.
Doctors reach for retapamulin to handle minor skin infections, like impetigo. Its focus is pretty narrow—tackle Staphylococcus aureus and Streptococcus pyogenes, two common skin troublemakers. Apply it as a thin layer. Seems easy enough. But no medicine plays out the same for everyone. Whenever I talk about ointments, neighbors and friends always ask about side effects, and for good reason.
I remember a pharmacy tech joking that “everything causes a rash,” but with retapamulin, it's not a punchline. Some folks run into irritation right at the spot where they apply it. That can look like redness, itch, or a swollen patch. In rare cases, some peeling sneaks in, too. In kids, where impetigo hits hardest, parents sometimes get nervous when the reddening drags out longer than expected.
A handful of people see the rash expand or a blister pop up after starting treatment. This reaction doesn't always mean the drug is at fault—it could be the infection itself or even a bit of both. I once watched a relative break out in small raised bumps after using a topical cream—not specifically retapamulin, but it hammered the point home: skin’s unpredictable.
Every so often, an allergic reaction pops up. That can send someone to the emergency room. These cases show up as hives, swelling around lips or eyes, and tightness in the chest. Reading through medical journals and the FDA’s reporting system, the rate sits low, but the severity can't be brushed aside. Doctors remind people to stop the drug and get help if they see these signs.
A different issue grows beneath the surface—bacterial resistance. When antibiotics get overused, bacteria start fighting back. The CDC has repeated this warning for years. While retapamulin sits on the skin rather than circulating in the blood, repetitive or unnecessary use helps create stubborn bugs. I saw a case at a community clinic where routine retapamulin use stopped working for a child who picked up skin infections often. Doctors adjusted the strategy, but the risk became clear.
Keeping it simple: only use retapamulin for what it’s meant to treat, and not on deep wounds, burns, or large body surfaces. Doctors need to remind families not to mix it with other ointments without advice. Cleaning hands before and after applying helps limit new infections or irritation. Reporting odd reactions to pharmacists ensures warning labels and research stay current.
Retapamulin works well for many, but each person’s story is different. Knowing what to watch for, staying in touch with a healthcare pro, and respecting antibiotics’ limits keeps both families and communities protected.
Doctors often reach for retapamulin ointment when trying to clear up minor skin infections. I remember working in the clinic, where parents brought in kids with scrapes or impetigo, looking for relief. Retapamulin acts directly on the bacteria, not the whole body, making it less likely to stir up side effects throughout the system. Developed specifically for skin, it takes on bacteria like Staphylococcus aureus and Streptococcus pyogenes.
Manufacturers and researchers focused on children during early studies and the FDA looks at these things closely. Retapamulin got its green light for use in kids as young as nine months old. That already tells parents a lot. Drug regulators don’t make these calls lightly. Clinical trials followed plenty of kids with infected scrapes and runny honey-yellow patches, the hallmark rash of impetigo. Results showed that retapamulin worked about as well as older creams like mupirocin, causing very few problems in its users. Pediatricians leaned on that track record.
Pediatricians see skin infections every day. A flaky patch near a child’s nose, a scrape picked at too many times—kids create their own trouble with bacteria. In all this, doctors want something safe and proven. The largest studies show that reactions to retapamulin mostly stay mild. Redness or irritation pop up sometimes, but there’s no mountain of reports about dangerous reactions.
I’ve seen families relieved, not just because the infection cleared up, but because they could avoid pills and the stress that comes with forcing medicine down a toddler’s throat. A thin layer of cream twice a day feels manageable for most people. If an ointment works on the surface without stirring up a child’s gut or mood, parents tend to accept it.
Retapamulin is easy to apply and doesn’t require complex dosing instructions. Still, some parents can’t find it or feel sticker shock when the pharmacist prints out the price. Insurance coverage varies, and in some places, older creams might come easier. That complicates things for pediatricians who want the best tool every time but must work with what families can access.
Resistance matters too. Some common skin germs grow less sensitive to old antibiotics. Retapamulin doesn’t fix resistance all by itself, but aiming directly at bacteria and avoiding unnecessary systemic drugs can keep broader resistance in check. Experts call for using topical antibiotics only when needed and for short stints, helping protect these drugs for future families.
Doctors stay alert for new warnings. So far, no big red flags have turned up in the years after approval. Still, kids with deeper wounds, extensive infections, or rare conditions need careful review. Used as directed, this ointment fits safely into the pediatrician’s toolbox.
Parents benefit when health pros talk through the options, explain how to use the medicine, and listen to worries. Good information beats internet rumors every time. Science shows retapamulin can help children with minor skin infections, especially impetigo, without heavy risk. Ongoing research and transparency help everyone stay on track, making it easier for families to trust these treatment choices as part of solid, evidence-based care.
Retapamulin ointment fights skin infections, especially impetigo. Doctors rely on it for children and adults, since it works where other antibiotics might stumble. You’ll see it sold as Altabax, and it comes in a small tube. This antibiotic only works on the skin. You won’t see it used for deeper or internal infections.
In the United States and many other countries, you can't just pop into a pharmacy and grab a tube off the shelf. Retapamulin needs a doctor’s prescription. Some people find this frustrating. Plenty of folks feel confident treating small skin infections at home. The pharmacy counter can turn into a wall. But these rules are rooted in medical oversight. Overuse—and misuse—of antibiotics leads to resistance. That problem doesn't seem urgent until you meet someone whose simple skin infection turned serious because nothing kills the superbug.
Doctors need to examine the problem before deciding on retapamulin. Some rashes look like impetigo but actually come from fungi or create a bigger danger if treated incorrectly. A doctor who sees your infection, checks your health history, and knows about local outbreaks offers a safety net. Not every country agrees with these limits. In some places, looser controls mean you could buy the ointment like toothpaste. Over time, these countries often report more resistant bugs and mistaken treatments.
Antibiotics used recklessly lose their punch. I’ve seen people grab an old tube from home or buy random ointments from overseas. They’ll put it on a bite or rash that turns out to be viral or fungal. I’ve watched those same people develop reactions, or the problem spreads until it means an ER visit. The Centers for Disease Control and Prevention points out that nearly 30% of antibiotics prescribed in outpatient settings go to problems where antibiotics do nothing. The solution? Respect antibiotics like retapamulin, and only use them when clearly needed. The prescription requirement keeps that discipline in place.
There are families who need easier access to care—time off work, childcare, and lack of insurance stack up. That stops parents from seeking help for a child with an oozing patch on their face. Telemedicine makes a dent. In some clinics, parents send a photo through a secure app, and a doctor reviews it promptly. Pharmacies in rural areas run nurse-led clinics that help with quick, safe assessments. These steps make the prescription requirement less of a roadblock and more of a checkpoint where a real expert weighs in.
If antibiotic resistance keeps marching forward, more countries might tighten rules. It’s one thing to want easier access, another to see entire communities hammered by hard-to-treat bacteria. Investment in primary care, telemedicine, and targeted education about when antibiotics help—these shape a smarter, more resilient system. As for now, grabbing retapamulin without a prescription only fuels more harm than good.
References:| Names | |
| Preferred IUPAC name | (11S,14R,15E,18S,19E,21S,23S,24R)-21,24-dihydroxy-14-[(2S,3R,4S,5E)-4-(2-hydroxyethoxy)-3-methoxy-3,5-dimethylhex-1-en-1-yl]-23-methoxy-13,17,25-trimethyl-12,15,18,22,26-pentaoxabicyclo[20.3.1]hexacosa-1(26),2,4,6,8,10,15,19-octaene-3,20-dione |
| Other names |
Altabax Altargo |
| Pronunciation | /ˌriː.təˈpæm.jʊ.lɪn/ |
| Identifiers | |
| CAS Number | 224452-66-8 |
| Beilstein Reference | 8535226 |
| ChEBI | CHEBI:71285 |
| ChEMBL | CHEMBL1201196 |
| ChemSpider | 21380438 |
| DrugBank | DB01248 |
| ECHA InfoCard | ECHA InfoCard: 100000694317 |
| EC Number | 613-665-4 |
| Gmelin Reference | 1043883 |
| KEGG | D06127 |
| MeSH | D000068875 |
| PubChem CID | 9813751 |
| RTECS number | SS7100000 |
| UNII | R8SVZ863HD |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C28H42N2O4S |
| Molar mass | 517.8 g/mol |
| Appearance | White to pale yellow crystalline powder |
| Odor | Odorless |
| Density | 0.94 g/cm³ |
| Solubility in water | Sparingly soluble in water |
| log P | 2.9 |
| Acidity (pKa) | 7.55 |
| Basicity (pKb) | 7.78 |
| Refractive index (nD) | 1.558 |
| Viscosity | Viscous liquid |
| Dipole moment | 3.11 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of Retapamulin: 0 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -8409.7 kJ/mol |
| Pharmacology | |
| ATC code | D06AX13 |
| Hazards | |
| Main hazards | May cause eye irritation. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GHS07 |
| Signal word | No signal word |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | Keep out of reach of children. For external use only. Avoid contact with eyes. If irritation develops, discontinue use and consult a physician. Use only as directed. |
| NFPA 704 (fire diamond) | NFPA 704: 2-2-0 |
| Flash point | > 224.6 °C |
| Lethal dose or concentration | LD50 (rat, oral): >2000 mg/kg |
| LD50 (median dose) | Rat oral LD50: >2000 mg/kg |
| PEL (Permissible) | Not established |
| REL (Recommended) | Topical: Apply to the affected area twice daily for 5 days |
| Related compounds | |
| Related compounds |
Pleuromutilin Lefamulin Valnemulin Tiamulin |
